Tesaro Adds Runway By Out-licensing Niraparib In Prostate Cancer
This article was originally published in Scrip
Executive Summary
Deriving income from letting somebody else pursue a direction you weren't prioritizing is always a good business strategy, which is what Tesaro Inc. did by out-licensing niraparib in prostate cancer to Janssen Biotech Inc. while retaining all other rights to the poly ADP-ribose polymerase (PARP) inhibitor.
You may also be interested in...
Medivation Hopes Details On Talazoparib Will Inspire Heightened M&A Bidding
Now in confidential talks with Sanofi and other buyout suitors, Medivation hopes to increase offers on the basis of its PARP inhibitor's dual-mechanism promise.
Janssen Oncology Strategy: Take A Holistic Approach To R&D
With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.